CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
CASTLE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Dermatologic | $54.84M | $42.57M | $38.42M | $34.52M | $29.89M | $25.03M | $22.54M | $20.72M | $18.17M | $13.64M | $12.84M | $10.34M | 53.0% | +83.5% |
| Dermatologic | $48.70M | $41.11M | $48.59M | $48.52M | $56.30M | $62.96M | $63.77M | $65.06M | $68.83M | $59.33M | $53.28M | $51.15M | 47.0% | -13.5% |
By region
From the segment and revenue-disaggregation notes of Castle Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.